Cardiovascular effects of noncardiovascular drugs

Circulation

Volumn 120, Issue 12, 2009, Pages 1123-1132

  Raj, Satish R ^a   Stein, C Michael ^a   Saavedra, Pablo J ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Drugs; Heart rate; Long QT syndrome; Pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMINOPHYLLINE; ANTHRACYCLINE; CABERGOLINE; CHLORPROMAZINE; CISPLATIN; CLONIDINE; CLOZAPINE; CYCLOPHOSPHAMIDE; DEXFENFLURAMINE; DOFETILIDE; DONEPEZIL; DULOXETINE; FENFLURAMINE; FLUOROURACIL; GEMCITABINE; IBUTILIDE; METHYLPREDNISOLONE; OLANZAPINE; PERGOLIDE; PHENYLPROPANOLAMINE; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; QUINIDINE; SILDENAFIL; SOTALOL; SUMATRIPTAN; UNINDEXED DRUG; ZOLEDRONIC ACID;

ATHEROSCLEROSIS; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR EFFECT; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONGENITAL HEART DISEASE; DEMENTIA; DISABILITY; DISEASE PREDISPOSITION; ERECTILE DYSFUNCTION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; LONG QT SYNDROME; METABOLIC SYNDROME X; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINUS TACHYCARDIA; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TORSADE DES POINTES; TREATMENT INDICATION; URINE INCONTINENCE; VALVULAR HEART DISEASE; VERTEBRA FRACTURE;

ANIMALS; ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HEART DEFECTS, CONGENITAL; HEART FAILURE; HEART VALVE DISEASES; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; HYPOTENSION; MYOCARDIAL INFARCTION;

EID: 70349668983     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.728576     Document Type: Review

References (122)

1. van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166:1016-1020.
2. Fujimoto S, Kondoh H, Yamamoto Y, Hisanaga S, Tanaka K. Holter electrocardiogram monitoring in nephrotic patients during methylpred-nisolone pulse therapy. Am J Nephrol. 1990;10:231-236.
3. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356: 1809-1822. (Pubitemid 46698462)
4. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896.
5. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357: 1799-1809.
6. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004; 44:2117-2124.
7. Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ. 2000;321:275.
8. Awan GM, Calderon E, Dawood G, Alpert MA. Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hyper-trophic obstructive cardiomyopathy. Am J Med Sci. 2000;320:69-71.
9. Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol. 1991;9:192-193.
10. Santini D, Tonini G, Abbate A, Di Cosimo S, Gravante G, Vincenzi B, Campisi C, Patti G, Di Sciascio G. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol. 2000;11:479-481.
11. Ciotti R, Belotti G, Facchi E, Cantu A, D'Amico A, Gatti C. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999;10:997.
12. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154:1502-1507.
13. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025-2032.
14. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
15. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153: 891-899.
16. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antide-pressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234-241. (Pubitemid 38314873)
17. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, Lambert G, Cox HS, Jennings G. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol. 1991;260:R817-R823.
18. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
19. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 1996;28:1836-1848.
20. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med. 1990;89:235-238.
21. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation. 1993;88:1832-1844.
22. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649-1671.
23. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Anti-psychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1167.
24. Zarate CA Jr, Patel J. Sudden cardiac death and antipsychotic drugs: do we know enough? Arch Gen Psychiatry. 2001;58:1168-1171.
25. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsy-chotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
26. Stratton SJ, Rogers C, Brickett K, Gruzinski G. Factors associated with sudden death of individuals requiring restraint for excited delirium. Am J Emerg Med. 2001;19:187-191.
27. Young D. Cardiovascular, psychiatric warnings strengthened on Adderall: FDA seeks stronger warning on all ADD drugs. July 28, 2006. American Society of Health-System Pharmacists. Available at: http:// www.ashp.org/import/news/ HealthSystemPharmacyNews/newsarticle. aspx?id/2267. Accessed March 5, 2009.
28. Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-326
29. Korsten MA, Rosman AS, Ng A, Cavusoglu E, Spungen AM, Radulovic M, Wecht J, Bauman WA. Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury. Am J Gastro-enterol. 2005;100:1560-1565.
30. Nieminen T, Lehtimaki T, Maenpaa J, Ropo A, Uusitalo H, Kahonen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmo-nary effects. Scand J Clin Lab Invest. 2007;67:237-245.
31. Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D. Clinical assessment of norepi-nephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:3202-3207.
32. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129-133.
33. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM. ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33: 273-282.
34. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002;287:719-725.
35. Santillo VM, Lowe FC. Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. Drugs Aging. 2006;23:795-805.
36. Chapple CR. A comparison of varying alpha-blockers and other phar-macotherapy options for lower urinary tract symptoms. Rev Urol. 2005; 7(suppl 4):S22-S30.
37. Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich). 2005;7:757-762.
38. Nieminen T, Koobi T, Tammela TL, Kahonen M. Hypotensive potential of sildenafil and tamsulosin during orthostasis. Clin Drug Investig. 2006;26:667-671.
39. Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'connor DT. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004;76: 139-153.
40. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826-1832.
41. Meadows M. FDA issues public health advisory on phenylpropanol-amine in drug products. FDA Consum. 2001;35:9.
42. Slordal L, Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006;29:567-586.
43. Johnson AG, Simons LA, Simons J, Friedlander Y, McCallum J. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol. 1993;35: 455-459.
44. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
45. Olukoga A, Donaldson D. Liquorice and its health implications. J R Soc Health. 2000;120:83-89.
46. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
47. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339: 713-718.
48. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J. 2002;144:1065-1073.
49. Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997:B8.
50. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation. 2007;116:2860-2865.
51. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318:604-610.
52. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280-1286.
53. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
54. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, Millan MJ. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor, III: agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther. 2002;303:815-822. (Pubitemid 35231258)
55. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higen-bottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609-616.
56. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117:870-874.
57. Guven A, Koksal N, Cetinkaya A, Sokmen G, Ozdemir R. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab. 2004;6:50-55.
58. Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, Lader M, Moore N. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005;28: 35-51.
59. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
60. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5-30.
61. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114-121.
62. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;CD003917.
63. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22:263-302.
64. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:173-183.
65. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19: 1613-1618.
66. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019. (Pubitemid 350236338)
67. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204-5212.
68. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110: 1233-1237.
69. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107:3133-3140.
70. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ. 1990;300:1174-1175.
71. Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart. 1999;81:221-223.
72. Goel M, Flaherty L, Lavine S, Redman BG. Reversible cardiomyopathy after high-dose interleukin-2 therapy. J Immunother. 1992;11:225-229.
73. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, Walker BR. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-865.
74. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
75. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: October 7, 2003. Circulation. 2003; 108:2941-2948.
76. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007; 335:497.
77. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861-866.
78. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60: 215-220.
79. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
80. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott ST, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
81. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006; 163:1273-1276.
82. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during anti-psychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59: 337-345.
83. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005; 62:19-28.
84. Tschoner A, Engl J, Rettenbacher M, Edlinger M, Kaser S, Tatarczyk T, Effenberger M, Patsch JR, Fleischhacker WW, Ebenbichler CF. Effects of six second generation antipsychotics on body weight and metabolism: risk assessment and results from a prospective study. Pharmacopsychiatry. 2009;42:29-34.
85. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147-1155.
86. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, d'Arminio MA, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371:1417-1426.
87. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
88. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
89. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, Barbarini G. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther. 2003;25: 2405-2418.
90. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
91. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, Meade D, Li XA, Zhu W, Uittenbogaard A, Wilson ME, Smart EJ. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389-397.
92. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endo-thelial dysfunction. Circulation. 2001;104:257-262.
93. Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez JJ, Levenson J, Simon A, Vittecoq D. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:490-493.
94. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
95. Moro H, Tsukada H, Tanuma A, Shirasaki A, Iino N, Nishibori T, Nishi S, Gejyo F. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS. 2004;18:687-690.
96. Brown WV. Safety of statins. Curr Opin Lipidol. 2008;19:558-562.
97. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
98. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-Term Arthritis Safety Study. JAMA. 2000;284: 1247-1255.
99. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
100. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk: where are we now? Nat Clin Pract Cardiovasc Med. 2005;2:290-300.
101. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471. (Pubitemid 46919772)
102. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-2643.
103. Rosen CJ. The rosiglitazone story: lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357:844-846.
104. Garbe E, Suissa S. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod. 2004;19:8-13.
105. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
106. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van HL, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712. (Pubitemid 38489892)
107. Kallen BA, Otterblad OP. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255-261.
108. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol. 2006;77:268-279.
109. Kallen BA, Otterblad OP, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20:209-214.
110. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354: 2443-2451.
111. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
112. Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther. 1998;36: 292-300.
113. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana School of Medicine (2007). Available at: http://medicine.iupui.edu/ clinpharm/ddis/table.asp. Accessed December 12, 2007.
114. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esome-prazole, lansoprazole, pantoprazole, and rabeprazole on human cyto-chrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
115. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
116. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
117. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52: 772-779.
118. Brown DD, Schmid J, Long RA, Hull JH. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavail-ability of digoxin when administered as tablets or capsules. J Clin Pharmacol. 1985;25:360-364.
119. Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol. 1988;25:229-233.
120. Barnes PM, Bloom B, Nahin R. Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007. Hyattsville, Md: National Center for Health Statistics; 2008.
121. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf. 2003;26:1075-1092.
122. Izzo AA, Di CG, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005; 98:1-14.